Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Madrigal Pharmaceuticals, Inc.

Biotech Giants: Who Leads in R&D Innovation?

__timestampIntra-Cellular Therapies, Inc.Madrigal Pharmaceuticals, Inc.
Wednesday, January 1, 20142122634568205000
Thursday, January 1, 20158771807454218000
Friday, January 1, 20169383153015934000
Sunday, January 1, 20177941900924390000
Monday, January 1, 201813216691325389000
Tuesday, January 1, 20198912483872324000
Wednesday, January 1, 202065782137184809000
Friday, January 1, 202188845513205164000
Saturday, January 1, 2022134715000245441000
Sunday, January 1, 2023180142000271823000
Loading chart...

Unleashing insights

Innovation in Biotech: A Comparative Analysis

In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Madrigal Pharmaceuticals, Inc. have demonstrated varying levels of investment in R&D, reflecting their strategic priorities.

From 2014 to 2023, Madrigal Pharmaceuticals has consistently increased its R&D spending, culminating in a 300% rise by 2023. This surge underscores Madrigal's aggressive pursuit of groundbreaking therapies. In contrast, Intra-Cellular Therapies, while also increasing its R&D budget, has shown a more moderate growth of approximately 750% over the same period.

The data reveals a fascinating trend: while both companies are committed to innovation, Madrigal's recent years show a more pronounced acceleration in R&D investment, potentially positioning it as a leader in the biotech innovation race.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025